Abstract
The aetiological agent of tuberculosis (TB), Mycobacterium tuberculosis, is responsible for millions of deaths annually. The increasing prevalence of the disease, the emergence of multidrug-resistant strains, and the devastating effect of human immunodeficiency virus co-infection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. Since the shikimate pathway is present and essential in algae, higher plants, bacteria, and fungi, but absent from mammals, the gene products of the common pathway might represent attractive targets for the development of new antimycobacterial agents. In this review we describe studies on shikimate pathway enzymes, including enzyme kinetics and structural data. We have focused on mycobacterial shikimate pathway enzymes as potential targets for the development of new anti-TB agents.
Keywords: 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase, 3-dehydroquinate synthase, 3-dehydroquinate dehydratase, shikimate 5-dehydrogenase, shikimate kinase, 5-enolpyruvylshikimate-3-phosphate synthase, chorismate synthase, antimycobacterial drug design
Current Drug Targets
Title: Mycobacterial Shikimate Pathway Enzymes as Targets for Drug Design
Volume: 8 Issue: 3
Author(s): R. G. Ducati, L. A. Basso and D. S. Santos
Affiliation:
Keywords: 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase, 3-dehydroquinate synthase, 3-dehydroquinate dehydratase, shikimate 5-dehydrogenase, shikimate kinase, 5-enolpyruvylshikimate-3-phosphate synthase, chorismate synthase, antimycobacterial drug design
Abstract: The aetiological agent of tuberculosis (TB), Mycobacterium tuberculosis, is responsible for millions of deaths annually. The increasing prevalence of the disease, the emergence of multidrug-resistant strains, and the devastating effect of human immunodeficiency virus co-infection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. Since the shikimate pathway is present and essential in algae, higher plants, bacteria, and fungi, but absent from mammals, the gene products of the common pathway might represent attractive targets for the development of new antimycobacterial agents. In this review we describe studies on shikimate pathway enzymes, including enzyme kinetics and structural data. We have focused on mycobacterial shikimate pathway enzymes as potential targets for the development of new anti-TB agents.
Export Options
About this article
Cite this article as:
Ducati G. R., Basso A. L. and Santos S. D., Mycobacterial Shikimate Pathway Enzymes as Targets for Drug Design, Current Drug Targets 2007; 8 (3) . https://dx.doi.org/10.2174/138945007780059004
DOI https://dx.doi.org/10.2174/138945007780059004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: New Developments in Drug and Vaccine Discoveries (Executive Editor: Aldar S. Bourinbaiar)]
Current Pharmaceutical Design Regulation of Cell Wall Synthesis and Growth
Current Molecular Medicine Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets
Current Medicinal Chemistry Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Withdrawal Notice: Highly Effective Synthesis of Dibromide of (+)-(1R, 2R)-and (-)-(1S, 2S)-1,2-diphenyl-1,2- ethylenediammonium (DPEN·2HBr) Assisted by Microwave
Current Green Chemistry The Ever Changing Face of Antibiotic Resistance: Prevailing Problems and Preventive Measures
Current Drug Metabolism HIV Vaccine Efficacy and Immune Correlates of Risk
Current HIV Research Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Patents Related to Pathogenic Human Coronaviruses
Recent Patents on Biotechnology Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives
Current Pharmaceutical Design The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications
Current Pharmaceutical Design Pulmonary Drug Delivery: A Role for Polymeric Nanoparticles?
Current Topics in Medicinal Chemistry Chemical Constituents and Biological Significance of the Genus Ilex (Aquifoliaceae)
The Natural Products Journal Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Meet Our Co-Editor
Central Nervous System Agents in Medicinal Chemistry Social Leverage of Intellectual Property: Road to the Development of Better Therapy for Tuberculosis
Recent Patents on Anti-Infective Drug Discovery